Long-term clinical evaluation of an adsorbent column (BM-01) of direct hemoperfusion type for beta 2-microglobulin on the treatment of dialysis-related amyloidosis.
The clinical efficacy and safety of a beta 2-microglobulin (beta 2M) adsorbent column, BM-01, on the treatment of dialysis-related amyloidosis were investigated in 7 hemodialysis patients for more than 6 months. The percent reduction of serum beta 2M was more than 60-70%, and the level at the end of each session was less than 10 mg/L in almost all patients. The amount of beta 2M removed was calculated as more than 200-300 mg/session. The results demonstrated that BM-01 performed very well for removing beta 2M, was capable of maintaining less than 25 mg/L of time average concentration (TAC) for beta 2M, and improved the clinical symptoms. Clinically severe side effects were not observed. We recommend that BM-01 should undergo further evaluation for its usefulness in the long-term treatment of dialysis-related amyloidosis, though treatment with the column may not be successful in preventing the onset of the disease.
Gejyo
F
F
Department of Clinical and Laboratory Science, Fukui Medical School, Matsuoka, Japan.
Teramura
T
T
Ei
I
I
Arakawa
M
M
Nakazawa
R
R
Azuma
N
N
Suzuki
M
M
Furuyoshi
S
S
Nankou
T
T
Takata
S
S
D000180:Acrylic Resins / Q000737:chemistry; D000327:Adsorption; D000368:Aged; D000686:Amyloidosis / Q000628:therapy*; D005260:Female; D006464:Hemoperfusion / Q000592:standards*; D006801:Humans; D008137:Longitudinal Studies; D008297:Male; D008567:Membranes, Artificial; D008768:Methylmethacrylates / Q000737:chemistry; D008875:Middle Aged; D006435:Renal Dialysis / Q000009:adverse effects*; D001613:beta 2-Microglobulin / Q000378:metabolism*
D000180:Acrylic Resins; D008567:Membranes, Artificial; D008768:Methylmethacrylates; D001613:beta 2-Microglobulin; C010504:polyacrylonitrile